NEW YORK, NY / ACCESSWIRE / July 19, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
CONTACT JAKUBOWITZ ABOUT FREQ:
https://claimyourloss.com/securities/frequency-therapeutics-inc-loss-submission-form/?id=17796&from=1
Class Period: November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
RLX Technology Inc. (NYSE:RLX)
CONTACT JAKUBOWITZ ABOUT RLX:
https://claimyourloss.com/securities/rlx-technology-inc-loss-submission-form/?id=17796&from=1
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline: August 9, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
Home Point Capital Inc. (NASDAQ:HMPT)
CONTACT JAKUBOWITZ ABOUT HMPT:
https://claimyourloss.com/securities/home-point-capital-inc-loss-submission-form/?id=17796&from=1
This lawsuit is on behalf of all persons and entities other than Defendants that purchased or otherwise acquired Home Point common stock pursuant and/or traceable to the Company's January 29, 2021 initial public offering.
Lead Plaintiff Deadline: August 20, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Home Point's aggressive expansion of its broker partners would dramatically increase the Company's expenses; (ii) the mortgage industry was anticipating industry-wide decreased gain-on-sale margins as a result of rising interest rates in 2021 and Home Point would be subject to the same competitive pressures; (iii) accordingly, the Company had overstated its business and financial prospects; and (iv) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law